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Abstract
Gout is a metabolic disorder characterized by hyperuricemia. Asymptomatic 
hyperuricemia ought not to be treated until arthritis; renal calculi or tophi 
become evident. The cornerstone of therapy of acute attack is often nonste-
roidal anti-inflammatory drugs (NSAIDs), barring specific situations wherein 
colchicine and corticosteroids do have a role. Usually NSAIDs with stronger 
anti-inflammatory action are used in high and quickly repeated doses and have 
a slower response response as compared to colchicine, they are better tolerated. 
Colchicine has a unique mechanism action. Intra-articular corticosteroids provide 
relief in acute attack and are given in patients having inability to tolerate NSAIDs 
and colchicine. Chronic gout requires treatments with drugs that either promote 
excretion (e.g., probenecid, lesinurad) or prevent its synthesis through inhibi-
tion of enzyme xanthine oxidase (allopurinol, febuxostat, etc.). Pegloticase and 
rasburicase, being a recombinant uricase enzyme, oxidize uric acid to highly 
soluble allantoin excreted in urine. In spite of these effective treatment modali-
ties, question arises on their safety profile. Newer treatment options are being 
extensively studied especially interleukin-1 (IL-1) inhibitors but their approval 
is still pending. The quest for an optimally designed drug with desirable efficacy 
and acceptable safety profile is still on.
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1. Introduction
Gout is a metabolic disorder characterized by increased deposition of urate 
crystals in the joints and connective tissue (tophi) and results in episodic acute 
or chronic arthritis. It also leads to deposition of urate crystals within the renal 
interstitium or nephrolithiasis [1]. Prevalence of gout has an uneven distribution 
throughout the globe with a higher prevalence in the Pacific countries. Blacks have 
been shown to have a decreased incidence/prevalence [2]. Gout affects 3% people 
of the western population with majority cases seen in middle-aged and elderly men 
and postmenopausal women [3]. Gout can be either a primary gout which is heredi-
tary or due to genetic anomaly in the genes responsible for excretion of uric acid. 
Secondary gout is majorly due to acquired causes of hyperuricemia. Deposition of 
urate crystal occurs when uric acid levels are >6.8 mg/dl.
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2. Causes
Gout can result from either increased production or due to decreased excretion 
of uric acid from the kidney or both. The causes of hyperuricemia can be listed 
separately into those for primary and secondary hyperuricemia.
1. Primary hyperuricemia
a. Increased production of purine
i. Idiopathic
ii. Enzyme defects (e.g., Lesch-Nyhan syndrome, glycogen storage 
diseases)
b. Decreased renal clearance
i. Idiopathic
2. Secondary hyperuricemia
a. Increased catabolism and turnover of purine
i. Myeloproliferative disorders
ii. Lymphoproliferative disorders
iii. Carcinoma and sarcoma
iv. Chronic hemolytic anemia
v. Cytotoxic drugs
vi. Psoriasis
b. Decreased renal clearance
i. Intrinsic kidney disease
ii. Drug induced (thiazides, low dose aspirin, pyrazinamide, loop 
diuretics, ethambutol, levodopa, ethanol cyclosporine, etc.)
iii. Hyperlactacidemia (lactic acidosis, alcoholism)
iv. Hyperketoacidemia (diabetic ketoacidosis, starvation)
v. Diabetes insipidus
vi. Bartter syndrome [4]
3. Pathophysiology
Following hyperuricemia, the urate crystals get deposited in the joints and 
connective tissues and activate monocytes or macrophages via Toll-like receptor 
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pathway mounting and innate immune response. This results in secretion of cyto-
kines including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) leading 
to endothelial activation and attraction of neutrophils to the site of inflammation. 
Neutrophils secrete inflammatory mediators that create an acidic environment, 
which further causes precipitation of urate crystals (Figure 1) [3].
4. Clinical presentation
Acute arthritis is the commonest early presentation of gout. It usually affects one 
joint precisely the metatarsophalangeal joint of the great toe. However, the disease 
can also have a polyarticular presentation and involve other joints like tarsal, ankle, or 
Figure 1. 
Schematic illustration of pathophysiology of gout.
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knee joints. In certain cases, it may also have a periarticular involvement involving the 
soft tissues. The intensity of the pain increases with the duration of the attack. Joints 
become swollen, tender with the overlying skin being warm, tense, and red in color. 
These symptoms most likely are associated with hyperthermia, and with time tophi 
start developing in the external ears, feet, olecranon, and prepatellar bursa [4, 5].
1. Laboratory investigations:
a. Serum uric acid levels: Used for diagnosing a patient of gout; however, 
these could be false positives and false negatives as it may not be raised 
at the time of the attack. It is also used as a reference while the patient is 
receiving hypouricemic therapy.
b. Peripheral leukocyte count is usually elevated during attack.
c. Aspiration of joint fluid and demonstration of sodium urate crystals are 
diagnostic. When observed under the microscope, these are needle-shaped 
crystals present both extracellularly and intracellularly. Increase in the 
number of crystals within the joint can lead to formation of a thick pasty, 
chalky joint fluid. When observed under compensated polarized light, 
the crystals appear to be brightly birefringent with negative elongations. 
In addition, the leukocyte count of the aspirated fluid is also found to be 
raised [1, 6].
2. Radiographic imaging:
a. X-ray: No changes seen in early stage of disease, later punched out erosions 
with an overhanging rim of cortical bone develop. Presence of this erosion 
adjacent to tophi is diagnostic.
b. Ultrasonography: Used when tophi are small and cannot be appreciated 
physically [4, 5].
5. Management of gout
Treatment modality in gout is aimed at:
1. Reducing the symptoms during acute attack
2. Reducing the recurrent attacks
3. Lowering serum urate levels [3]
Treatment can be divided into non-pharmacological and pharmacological.
5.1 Non-pharmacological treatment
Patients upon being diagnosed with hyperuricemia should be advised diet with 
less purine content (refined cereals, white bread, milk, peanut butter, fruits, nuts, 
tomato, green vegetables, etc.). Alcohol consumption should be kept at minimum; 
intake of whiskey and wine should be preferred rather than beer. Organ meats and 
beverages sweetened with high fructose corn syrup should be avoided. In addition, 
high intake of liquid diet should be advised to facilitate urine output of 2 L or more, 
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which favors urate excretion. Patients with asymptomatic hyperuricemia ought not 
to be given pharmacological treatment until arthritis or renal calculi develop.
5.2 Pharmacological treatment
Pharmacotherapy of gout is divided into:
1. For acute gout
a. Nonsteroidal anti-inflammatory drugs (NSAIDs)
b. Colchicine
c. Corticosteroids
2. For chronic gout
a. Uricosurics (probenecid, sulfinpyrazone, benzbromarone, lesinurad)
b. Uric acid synthesis inhibitors (allopurinol, febuxostat)
c. Uricase (rasburicase, pegloticase) [7]
5.2.1 For acute gout
1. NSAIDs: Oral agents are preferred and are effective of acute gout. The drugs 
with a stronger anti-inflammatory action are used. They provide relief by 
inhibiting cyclooxygenase-2(COX-2)-mediated prostaglandin synthesis at the 
site of injury; however, there are certain additional mechanisms pertaining 
to some drugs also. The NSAIDs provide symptomatic relief from pain and 
inflammation. In addition, they are also used initially as a bridging therapy 
along with uric acid synthesis inhibitors to prevent development of symptoms 
of acute gouty arthritis due to mobilization of urate from the tissues. NSAIDs 
are contraindicated in conditions like active peptic ulcer disease, impaired 
kidney function, and history of allergic reactions. The drugs used more often 
are naproxen, piroxicam, diclofenac, indomethacin, and etoricoxib [5, 8].
a. Naproxen: It is a nonselective COX inhibitor having a stronger anti-
inflammatory activity and potent in inhibiting leucocyte migration. Peak 
anti-inflammatory effect starts after 2–4 weeks.
i. Pharmacokinetics: It is absorbed in fullest extent after oral administra-
tion and is absorbed slowly via rectal route. It is 99% plasma protein 
bound with a variable t1/2. With advancement of age, the renal function 
declines, and the t1/2 increases. It is 30% metabolized in liver, and its 
excretion occurs via urine. It crosses placenta and is also excreted in milk.
ii. Dosage: It is started in a dosage of 750 mg stat followed by 250 mg 
twice or thrice daily.
iii. Adverse effects: These are mostly gastrointestinal in nature like 
heartburn, nausea, dyspepsia, abdominal pain, constipation, diarrhea, 
and stomatitis. CNS side effects like headache, drowsiness, headache, 
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dizziness, and vertigo and other adverse effects like  
pruritis, diaphoresis, loss of renal function, angioedema, and throm-
bocytopenia can also occur. Reports also suggest that it can also 
increase the risk of myocardial infarction [8].
b. Piroxicam: Another nonselective COX inhibitor having a potent anti-
inflammatory action and longer duration of action. In addition to inhibi-
tion of COX enzyme, it has also been proposed to inhibit neutrophil 
activation and inhibition of proteoglycanase and collagenase in cartilage.
i. Pharmacokinetics: Completely absorbed upon oral administration 
and undergoes enterohepatic circulation. It is 99% protein bound and 
is metabolized in the liver by CYP2C9. t1/2 is approximately between 
15 and 20 hours. Steady state plasma concentrations are attained in 
7–12 days and further excreted in urine and feces.
ii. Dosage: It is given in a dose of 20 mg daily.
iii. Adverse effects: Experienced by 20% of the patients and eventually 
5% of the recipients discontinue the treatment. The adverse effects 
are similar to those of naproxen though more in intensity. It is not a 
first-line agent for treatment of pain and inflammation in gout among 
all NSAIDs [9].
c. Indomethacin: A potent nonselective COX inhibitor. It also inhibits motil-
ity of polymorphonuclear lymphocytes, inhibits synthesis of mucopoly-
saccharides, and has a direct COX-independent vasoconstrictor effect.
i. Pharmacokinetics: It has a good bioavailability after oral administra-
tion. Peak plasma concentrations are achieved within 1–2 hours. It is 
99% plasma protein bound, and concentration within the synovial 
fluid equals that of plasma concentration in 5 hours of oral administra-
tion. It also undergoes enterohepatic circulation due to which it has a 
variable t1/2 and averages out to be about 2 hours.
ii. Dosage: It is given in a dose of 25 mg twice of thrice daily or  
75–100 mg at night.
iii. Adverse effects: Experienced by majority of patients but in particu-
lar elderly. The gastrointestinal adverse effects are similar as that 
of naproxen though it can also cause ulcerations within the bowel. 
Certain CNS adverse effects like headache, dizziness, vertigo, and 
mental confusion can also occur. It should be prescribed cautiously to 
patients with epilepsy, psychiatric disorders or Parkinson’s disease as 
they are at more risk of eliciting serious CNS side effects. It can also 
cause certain hematopoietic disorders like neutropenia, thrombocy-
topenia, and rarely aplastic anemia. Probenecid increases the plasma 
concentration of indomethacin, so the dose should be lowered in 
such case [10].
d. Etoricoxib: It is a newer selective COX-2 inhibitor having the highest 
COX-2-selective activity. It is given only in patients with high risk of peptic 
ulcer, perforation, or bleeding.
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i. Pharmacokinetics: It is incompletely absorbed, has a longer t1/2 
between 20 and 60 hours, metabolized in the liver, and excreted via 
urine. Hepatic impairment promotes its accumulation in the body, 
whereas renal impairment does not.
ii. Dosage: It is given in a dosage of 60–120 mg once daily.
iii. Adverse effects: Dyspepsia, abdominal pain, pedal edema, rise in 
BP, dry mouth, aphthous ulcers, taste disturbance, and paresthesias. 
It should not be used in patients with or at risk of cardiovascular or 
cerebrovascular disease as it can cause prothrombotic events [9].
2. Colchicine: It is one of the oldest drugs available for treatment of acute gout. 
An alkaloid obtained from Colchicum autumnale having no analgesic or anti-
inflammatory property nor having any effect on inhibiting synthesis or increas-
ing excretion of uric acid. It is not used as a first-line drug due to its narrow 
therapeutic window and increased side effects. It suppress gouty inflammation 
by various mechanisms: It (a) prevents granulocyte migration into the inflamed 
joint, (b) inhibits release of glycoprotein which causes aggravates inflamma-
tion by forming lactic acid and by releasing lysosomal enzymes which lead to 
joint destruction, and (c) binds to an intracellular protein called tubulin and 
causes depolymerization and disappearance of microtubules in granulocytes. 
Collectively, these prevent migration of granulocytes into the area of inflam-
mation and further prevent it. It also limits monosodium urate crystal-induced 
NALP3 inflammasome activation and subsequent formation of IL-1β and IL-18. 
It exerts various other actions also like lowering of body temperature, increased 
sensitivity to central depressants, and depression of respiratory center. 
Colchicine is also used in management of chronic gout as bridging therapy with 
uric acid synthesis inhibitors to prevent development of symptoms of acute 
gouty arthritis initially due to mobilization of urate from tissues.
a. Pharmacokinetics: It has a rapid but variable absorption via oral route 
with no effect of food on its absorption. It achieves peak plasma con-
centrations within 0.5–2 hours. It is 39% plasma protein bound; larger 
volume of distribution due to formation of colchicine-tubulin complexes 
with different tissues and undergoes enterohepatic circulation account-
ing for its longer t1/2, i.e., 31 hours. It is metabolized mainly by oxidative 
demethylation with the help of enzyme CYP3A4. Approximately 40–65% 
of colchicine is excreted unchanged in urine, and the main organs with 
high colchicine concentration are the kidney, spleen, and liver sparing 
the heart, skeletal muscles, and brain. Colchicine acts as a substrate for 
P-glycoprotein efflux and is contraindicated in patients with hepatic or 
renal impairment already on CYP3A4 or P-glycoprotein inhibitor therapy.
b. Dosage: Individualization needs to be performed as per the age, renal/
hepatic function, and concomitant medications and is administered only 
by oral route. A gap of 7–14 days should be present between courses of 
gout treatment with colchicine therapy to avoid accumulation of drug 
and further toxicity. Patients suffering from cardiac, hepatic, or renal 
disease are better off with NSAIDs or glucocorticoids. For the treatment 
of acute gout flare, two tablets 0.6 mg each should be taken first followed 
by a single 0.6 mg tablet after 1 hour. Pain, swelling, and redness subside 
within 12 hours and are resolved by 48–72 hours.
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For prophylaxis in patients with recurrent gout having less than one attack per 
year, 0.6 mg tablet is to be taken 3 or 4 days per week; those having more than 
1 attack per year, 0.6 mg tablet is to be taken daily; and those having severe 
attacks, 0.6 mg tablets are to be taken twice daily. Caution is to be taken in 
patients with hepatic or renal mutilation as the drug cannot be removed by 
hemodialysis.
c. Adverse effects: The most common adverse effects are gastrointestinal 
(nausea, vomiting, diarrhea, and abdominal pain) as the drug undergoes 
enterohepatic circulation and is in constant state of contact with gastric 
mucosa. It is advised to stop the drug on emergence of these symptoms. 
Other adverse effects include myelosuppression, leucopenia, granulocyto-
penia, neutropenia, aplastic anemia, and rhabdomyolysis [3–5, 11].
3. Corticosteroids: They provide symptomatic relief to a patient of acute gout 
during attacks and prevent further attacks by their anti-inflammatory action. 
They are mostly indicated in patients who cannot be prescribed NSAIDs and 
colchicine. Glucocorticoids provide their anti-inflammatory effect by various 
mechanisms: (a) induce production of lipocortin which inhibits phospholi-
pase A2 and decreases production of arachidonic acid leading to decrease in 
synthesis of inflammatory mediators like prostaglandins, leukotrienes, and 
platelet-activating factor; (b) inhibit synthesis and release of cytokines (IL-1, 
IL-4, IL-6, and TNF-α) with reduced activation of T cells and fibroblast prolif-
eration, thereby reducing process of chemotaxis; and (c) inhibit pro-inflam-
matory transcription factors like nuclear factor-κB and activating protein 
which leads to decreased enhancement of transcription of genes for COX-2, 
cytokines, and nitric oxide synthase (iNOS). The drugs used are prednisolone, 
methylprednisolone, and triamcinolone with the advantage of being given by 
oral route, intravenous route, or intra-articular administration.
a. Pharmacokinetics: All these three have an intermediate duration of action 
(12–36 hours). They are 90% plasma protein bound. They mainly bind to 
corticosteroid-binding globulin. They are metabolized both at hepatic and 
extrahepatic sites.
b. Dosage: Prednisolone is given in a dose of 40–60 mg per day orally or 40 mg 
per day intravenously. They are given at the initial dose for 2–5 days and then 
tapered over 7–10 days. Triamcinolone is given intra-articularly at a dose 
of 10–40 mg depending on the size of the joint. They should be taken early 
morning so as to have less effect of hypothalamic-pituitary axis suppression.
c. Adverse effects: They are an extension of their pharmacological actions 
seen with extended therapy. The adverse effects include altered distribu-
tion of fat throughout the body, edema, hypokalemia, hypertension, 
suppression of hypothalamic-pituitary axis, osteoporosis, hyperglycemia, 
peptic ulcer, cataract formation, glaucoma, myopathy, muscle wast-
ing, susceptibility to infections, and central nervous system (CNS) side 
effects like psychiatric disturbances, acne, weight gain, and hyperlipi-
demia [4, 12].
5.2.2 For chronic gout
1. Uricosurics: These are drugs which favor excretion of uric acid from the body.
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a. Probenecid: It is a highly lipid-soluble benzoic acid derivative. It mainly 
acts by inhibiting transport of organic acids across the epithelial barrier. 
Reabsorption of uric acid is inhibited by its action on the organic anion 
transporters (OAT) mainly urate transporter-1 (URAT-1). In addition, 
it also hampers pharmacokinetic properties of many other drugs also, 
i.e., retards tubular secretion of methotrexate and active metabolite of 
clofibrate, inhibits renal secretion of inactive glucuronide metabolites of 
naproxen, ketoprofen, and indomethacin thereby increasing their plasma 
concentration, hampers transport of drugs such as penicillin G, and raises 
the plasma levels of β lactam.
i. Pharmacokinetics: Complete absorption occurs after oral adminis-
tration and attains peak plasma concentrations within 2–4 hours. 
It has a dose-dependent t1/2 and varies between less than 5 to more 
than 8 hours. It is 85–95% bound to plasma albumin, and the 
unbound part is excreted by glomerular filtration and active tubular 
secretion.
ii. Dosage: Initially it is given in a dose of 250 mg twice daily and increased 
over 1–2 weeks to 500–1000 mg twice daily. Patient should be advised 
to increase the daily water intake to prevent formation of renal stones as 
probenecid increases urinary urate levels. De-escalation is to be started 
after 6 months of treatment if the uric acid levels are favorable.
iii. Adverse effects: Mild gastrointestinal irritation is mostly seen and 
that too with higher doses. It should be avoided in patients with 
creatinine clearance 50 ml/min and is also ineffective in these patients. 
Overdosage leads to CNS stimulation, convulsions, and death due to 
respiratory failure. It is contraindicated in patients with history of 
renal stones [13, 14].
b. Sulfinpyrazone: It has neither analgesic nor neither anti-inflammatory 
property. It inhibits tubular reabsorption of uric acid. Due to its higher 
incidence of gastric irritation and other side effects, it is not used nowa-
days [15].
c. Benzbromarone: It is a reversible urate anion exchanger inhibitor present 
in the proximal tubule. It has not been approved by the United States 
(US) Food and Drug Administration (FDA) due to its risk of causing 
severe hepatotoxicity; however, it is used as a potent uricosuric in certain 
Southeast Asian countries [16].
d. Lesinurad: Another uricosuric which has been approved for use in combi-
nation therapy with a xanthine oxidase inhibitor. It acts by inhibiting the 
transporters URAT-1 and OAT-4 and decreasing reabsorption of uric acid.
i. Pharmacokinetics: It has a fast oral absorption showing 100% avail-
ability and is largely plasma protein bound. It has a t1/2 of 5 hours, 
metabolized by CYP2C9, and is excreted in urine and feces.
ii. Dosage: Given at a dosage of 200 mg per day along with a xanthine 
oxidase inhibitor. It should not be used in patients with creatinine 
clearance 45 ml/min.
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iii. Adverse effects: Black box warning has been issued by the US FDA 
against its use as monotherapy due to risk of causing acute renal 
failure. It has also propensity to cause an increase in serum creatinine 
levels. Other adverse effects like headache and gastritis can also occur. 
Interruption with xanthine oxidase inhibitor requires stoppage of 
lesinurad also [14].
2. Uric acid synthesis inhibitors (Xanthine oxidase inhibitors)
a. Allopurinol: This compound was initially produced as an antineoplastic 
agent and was later found to lack that property. Later it was found to have 
xanthine oxidase enzyme-inhibiting property. Xanthine oxidase enzyme is 
responsible for conversion of hypoxanthine and xanthine into urate, and by 
inhibiting this enzyme, allopurinol prevents formation of urate. Allopurinol 
in low concentrations acts as a competitive and as a noncompetitive inhibi-
tor at high concentrations of xanthine oxidase enzyme. The formation of 
oxypurinol (alloxanthine), its primary metabolite, and its long persever-
ance in tissues is majorly responsible for its activity. Oxypurinol inhibits the 
reduced form of xanthine oxidase enzyme. Conversion of hypoxanthine to 
xanthine takes place in the presence of xanthine oxidase enzyme which is 
also blocked by allopurinol (inhibition of de novo purine synthesis). The 
purines are mainly excreted by the kidney. In the absence of allopurinol, the 
major purine excreted is uric acid, whereas it is hypoxanthine, xanthine, 
and uric acid in the presence of allopurinol. This treatment leads to excess 
purine load in the kidney which might lead to a risk of xanthine stones 
which can be minimized by increasing the fluid intake and alkalization 
of urine. It also helps in dissolution of tophi and decreases the chances of 
development and progression of chronic gouty arthritis. It also prevents 
development of nephropathy by preventing formation of uric acid stones; 
however, it cannot restore the renal function after injury to the renal tissue 
has occurred, but it may retard the progression. Initially on starting the 
therapy, chances of acute attack of gouty arthritis increase due to movement 
of uric acid outside from the tissues, and this can be concealed by giving 
NSAIDs and colchicine along with allopurinol. Allopurinol is also used 
in patients undergoing chemotherapy for hematological malignancies to 
prevent hyperuricemia and consequently gout.
i. Pharmacokinetics: It has a fast oral absorption with peak plasma concen-
trations achieved in 60–90 min. Plasma half-life of allopurinol is 1–2 hours 
and that of oxypurinol is 18–30 hours which allows for once daily dos-
ing. It undergoes metabolism which leads to formation of its metabolite 
oxypurinol. Around 20% of unabsorbed drug is excreted in feces within 
48–72 hours, and other 10–30% of unabsorbed drug is excreted in urine. 
It is not bound to any plasma protein and is distributed in total tissue water 
except the brain. Oxypurinol is excreted via glomerular filtration.
ii. Dosage: It can be given both as an oral and intravenous preparation. The 
main aim of treatment is to decrease the uric acid level to 6 mg/dl. The 
drug is initially started at 100 mg/day for patients with glomerular filtra-
tion >40 mg/min and is increased by 100 mg weekly. It is usually given 
in once daily dosing, but dosing above 300 mg should be divided accord-
ingly. Dosage in patients with reduced glomerular filtration (<40 mg/
min) should be less than that of a normal person (>60 mg/min).
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iii. Adverse effects: It is generally well tolerated. However, the most com-
mon adverse effects are hypersensitivity reactions which are seen after 
months and years of treatment, and this can further precipitate into 
serious reactions if the drug is not stopped. The cutaneous reactions 
seen are mainly pruritic, erythematous, or maculopapular eruption. 
It is contraindicated in patients who previously have experienced 
serious reactions with it, in nursing mothers and in children except 
those with malignancy and inborn errors of metabolism. It increases 
half-life of probenecid and enhances its uricosuric effect; on the other 
hand, probenecid increases clearance of oxypurinol, thereby increas-
ing the dose required. Allopurinol also inhibits enzymatic activation 
of mercaptopurine and azathioprine by xanthine oxidase enzyme 
which should be kept in mind in patients undergoing chemotherapy. It 
also increases risk of bone marrow suppression if given with cytotoxic 
drugs and interferes with metabolic inactivation of some drugs like 
warfarin.
b. Febuxostat: Another xanthine oxidase inhibitor which has been approved 
for treatment of hyperuricemia in gout though it is not recommended for 
treatment of asymptomatic hyperuricemia, having the advantage of being 
more potent, selective, no dose reduction in renal disease patients, and 
less chances of causing allergic reactions. Febuxostat is used in conditions 
when patient is intolerant to allopurinol or when it is contraindicated. 
It is a non-purine inhibitor of xanthine oxidase enzyme inhibiting both 
reduced and oxidized forms of the enzyme. It usually requires concurrent 
treatment with NSAIDs or colchicine.
i. Pharmacokinetics: It has a rapid absorption with peak plasma concen-
trations being achieved after 1–1.5 hours of drug intake. The half-life 
is around 5–8 hours and is metabolized both by conjugation by UGT 
enzymes (UGT1A1, UGT1A3, UGT1A9, and UGT2B7) and oxidized 
by CYP enzymes (CYP1A2, CYP2C8, CYP2C9) and non-CYP enzymes 
indicating possibility of drug-drug interactions. It is excreted by both 
hepatic and renal routes. No dose reduction is required in case of mild 
to moderate hepatic or renal impairment.
ii. Dosage: It is initiated at 40 mg/day and is increased as per the patient’s 
uric acid levels.
iii. Adverse effects: The most common adverse effect seen with it is 
abnormality with liver function tests, nausea, joint pain, and rash, 
so regular monitoring of liver function is required. It can also cause 
an increase in gout flares as during the therapy there is mobiliza-
tion of urate crystals from the tissue deposits due to a decrease in 
the uric acid levels. Patients should also be regularly checked for 
any cardiovascular complications. Drug levels of theophylline, 
mercaptopurine, and azathioprine, which are metabolized by xan-
thine oxidase enzyme, are increased if given with febuxostat and 
febuxostat and are contraindicated in patients taking azathioprine or 
mercaptopurine.
3. Uricase: It is an enzyme which is present in birds which converts uric acid into 
soluble allantoin which is easily excreted.
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a. Rasburicase: A recombinant uricase which has been shown to lower 
urate levels much efficiently than allopurinol. It has been indicated as the 
initial management for elevated uric acid levels in children and adults 
suffering from leukemia, lymphoma, and solid tumor malignancies 
and undergoing chemotherapy leading to significant hyperuricemia. 
However, there are certain limitations with it like formations of antibod-
ies against it.
i. Dosage: It is given as 0.2 mg/kg IV as infusion over 30 minutes every 
day up to 5 days.
ii. Adverse effects: Certain adverse effects like nausea, headache, con-
stipation, diarrhea, hemolysis in glucose-6-phosphate dehydrogenase 
(G6PD) deficient patients, methemoglobinemia, acute renal failure, 
and anaphylaxis are seen with it.
b. Pegloticase: It is pegylated uricase converting uric acid into soluble allan-
toin. It is used for the treatment of severe, treatment refractory, chronic 
gout or when other urate-lowering therapies are contraindicated. Problem 
of development of antibodies against it is seen with pegloticase also.
i. Dosage: It is administered at 8 mg every 2 weeks as an infusion.
ii. Adverse effects: Vomiting, nausea, chest pain, constipation, diarrhea, 
erythema, pruritis, urticaria, hemolysis in G6PD deficient patients, 
and anaphylaxis are certain adverse effects seen with it. Black box 
warning has been issued by US FDA against pegloticase which advises 
that the drug should only be administered in health-care settings and 
only by health-care professionals to manage anaphylactic reactions and 
other serious reactions [11, 17].
6. Recent developments
a. Arhalofenate: It has been synthesized showing a dual mechanism of action but 
is still pending in approval. It acts as a partial agonist to peroxisome prolifer-
ator-activated receptor-γ (PPAR-γ) and inhibits expression of IL-1, thereby 
inhibiting renal absorption of uric acid in the kidney by URAT-1, OAT-4, and 
OAT-10 transporters [18].It was initially synthesized as a drug for the manage-
ment of type 2 diabetes mellitus but was also found to have anti-flare and 
uricosuric property. Its phase II study has been completed showing positive 
results, and further results from ongoing studies are awaited [19].
b. Interleukin-1 inhibitors (anakinra, canakinumab, rilonacept): These prevent 
attraction of neutrophils at the joint site. The drugs in this class are anakinra, an 
interleukin-1 receptor antagonist; canakinumab, a monoclonal antibody against 
interleukin-1 beta; and rilonacept, a chimera constituting of IgG domains and 
extracellular components of interleukin-1 receptor. All these have been shown to 
have efficacy in acute gout but still have not been approved by the drug regula-
tory authorities [7]. However, these are approved for their use in other diseases 
like rheumatoid arthritis and cryptoporphyrin-associated periodic syndrome. 
They are contraindicated in patients with previous hypersensitivity reactions to 
these drugs and any serious active infection. Further application concomitant 
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live attenuated vaccine is to be avoided. Concern of immunosuppression with 
their use has been an important reason for their disapproval [20].
c. Verinurad: It is also a uricosuric which inhibits the reabsorption of uric acid by 
acting on the URAT-1. It has been shown to be 3 times more potent than ben-
zbromarone and 100 times more potent than probenecid and has completed 
phase II clinical trial.
d. Tranilast: It is a moderately sedative H1 anihistaminic drug, which is used in 
management of bronchial asthma and other allergic conditions in Japan. It has also 
been shown to reduce serum uric acid levels by inhibition of URAT-1 transporter 
and promoting excretion of urate. In addition, it has also been shown to decrease 
the inflammation induced by monosodium crystals in vivo by reducing leukocyte 
infiltration and plasma extravasation similar to colchicine and indomethacin, 
thereby causing flare reduction. It has completed its phase II clinical trial.
e. Levotofisopam: It is an S-enantiomer of racemic tofisopam which is a ben-
zodiazepine derivative which has been approved in the United States for the 
management of anxiety. Phase I clinical trial has been completed, phase II 
studies are underway, and results are awaited.
f. Topiroxostat: It is a selective xanthine oxidase inhibitor. Its mechanism of 
action is different from that of febuxostat such that it acts as a hybrid inhibi-
tor. It not only acts as a chemical structure based xanthine oxidase enzyme 
inhibition but also covalently binds to molybdenum in the active center 
during the hydroxylation process of the enzyme. The pharmacokinetics of 
topiroxostat is unaltered by mild to moderate renal impairment. It has a 
half-life of around 20 hours, and enzyme activity takes time to recover even 
after the drug has been metabolized. In patients with concurrent moderate 
renal impairment and hyperuricemia, a fall in serum urate and albumin levels 
has been reported. It has been approved by the Pharmaceuticals and Medical 
Devices Agency, in Japan in the year 2013, in a dose of 20–80 mg twice daily.
g. Ulodesine: It acts by inhibiting purine nucleotide phosphorylase (PNP) which 
is an enzyme that acts one-step before xanthine oxidase in production of urate. 
Initial concerns were shown due to inhibition of PNP enzyme due to its absence 
in immunodeficient patients and in patients suffering from immunologic disor-
ders, but nothing has been reported in studies until date. Phase II studies have 
been completed, and further studies are awaited [19].
We all authors share the opinion that therapy of the chronic tophaceous gout is 
still far from optimal. Despite availability of several agents, none has been consid-
ered as ideal due either to their undesirable adverse effects profile, limited utility 
in patients of renal impairment, inadequate response or failure to reverse existing 
osseous lesions, and dissolution of tophi from the tissues. We anticipate that newer 
drugs that are being developed with different mechanism of actions might address 
these issues, but only time will prove their worth.
7. Conclusions
Gout is a metabolic disorder due to the rise in uric acid levels in the body leading 
to development of gouty arthritis. Its management requires both pharmacological 
Recent Advances in Gout
14
and non-pharmacological intervention. Newer drugs targeting various inflamma-
tory mediators, enzymes, or transporters are in different phases of clinical develop-
ment. Until date, none has reached to phase III and yet to get an approval from 
regulatory bodies. The quest for an optimally designed drug with desirable efficacy 
and acceptable safety profile is still on.
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COX cyclooxygenase
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IL interleukin
iNOS nitric oxide synthase
NSAIDs nonsteroidal anti-inflammatory drugs
OAT organic anion transporters
PNP purine nucleotide phosphorylase
t1/2 half-life
TNF tumor necrosis factor
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